Distinct responses of human peripheral blood cells to different misfolded protein oligomers

Increasing evidence indicates that peripheral immune cells play a prominent role in neurodegeneration connected to protein misfolding, which are associated with formation of aberrant aggregates, including soluble protein misfolded oligomers. The precise links, however, between the physicochemical features of diverse oligomers and their effects on the immune system, particularly on adaptive immunity, remain currently unexplored, due partly to the transient and heterogeneous nature of the oligomers themselves. To overcome these limitations, we took advantage of two stable and well‐characterized types of model oligomers (A and B), formed by HypF‐N bacterial protein, type B oligomers displaying lower solvent‐exposed hydrophobicity. Exposure to oligomers of human peripheral blood mononuclear cells (PBMCs) revealed differential effects, with type B, but not type A, oligomers leading to a reduction in CD4+ cells. Type A oligomers promoted enhanced differentiation towards CD4+CD25HighFoxP3+ Tregs and displayed a higher suppressive effect on lymphocyte proliferation than Tregs treated with oligomers B or untreated cells. Moreover, our results reveal Th1 and Th17 lymphocyte differentiation mediated by type A oligomers and a differential balance of TGF‐β, IL‐6, IL‐23, IFN‐γ and IL‐10 mediators. These results indicate that type B oligomers recapitulate some of the biological responses associated with Parkinson's disease in peripheral immunocompetent cells, while type A oligomers resemble responses associated with Alzheimer's disease. We anticipate that further studies characterizing the differential effects of protein misfolded oligomers on the peripheral immune system may lead to the development of blood‐based diagnostics, which could report on the type and properties of oligomers present in patients.

[1]  Shuwen Xu,et al.  Mild Cognitive Impairment Patients Have Higher Regulatory T-Cell Proportions Compared With Alzheimer's Disease-Related Dementia Patients , 2021, Frontiers in Aging Neuroscience.

[2]  Z. Yao,et al.  Intraperitoneal injection of IFN-γ restores microglial autophagy, promotes amyloid-β clearance and improves cognition in APP/PS1 mice , 2020, Cell Death & Disease.

[3]  Ximena Zottig,et al.  Protein Supramolecular Structures: From Self-Assembly to Nanovaccine Design , 2020, Nanomaterials.

[4]  B. Becher,et al.  Glial Cells as Regulators of Neuroimmune Interactions in the Central Nervous System , 2020, The Journal of Immunology.

[5]  Young Ho Park,et al.  Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study. , 2020, Journal of Alzheimer's disease : JAD.

[6]  T. Tokuda,et al.  Combined use of CSF NfL and CSF TDP‐43 improves diagnostic performance in ALS , 2019, Annals of clinical and translational neurology.

[7]  F. Sellebjerg,et al.  Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease , 2019, Annals of neurology.

[8]  L. Buée,et al.  NLRP3 inflammasome activation drives tau pathology , 2019, Nature.

[9]  Zhenxiang Zhao,et al.  Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson's disease. , 2019, Annals of translational medicine.

[10]  Huali Wang,et al.  Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[11]  F. Quintana,et al.  Meningeal Memories of Viral Infection , 2019, Trends in Neurosciences.

[12]  C. Dobson,et al.  Differential interactome and innate immune response activation of two structurally distinct misfolded protein oligomers. , 2019, ACS chemical neuroscience.

[13]  D. Maric,et al.  Infection drives meningeal engraftment by inflammatory monocytes that impairs CNS immunity , 2019, Nature Immunology.

[14]  S. Amor,et al.  Neuroimmunology – the past, present and future , 2019, Clinical and experimental immunology.

[15]  V. Baekelandt,et al.  Peripheral Inflammation Regulates CNS Immune Surveillance Through the Recruitment of Inflammatory Monocytes Upon Systemic α-Synuclein Administration , 2019, Front. Immunol..

[16]  H. Wiendl,et al.  Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease , 2018, Front. Neurol..

[17]  Yong Cheng,et al.  Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis , 2018, Front. Immunol..

[18]  K. Blennow,et al.  CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease , 2018, Neurology.

[19]  M. Cosentino,et al.  Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients , 2018, Journal of Neuroinflammation.

[20]  J. Kornhuber,et al.  Imbalance of Circulating Th17 and Regulatory T Cells in Alzheimer’s Disease: A Case Control Study , 2018, Front. Immunol..

[21]  S. Amor,et al.  Inflammation in CNS neurodegenerative diseases , 2018, Immunology.

[22]  D. Altmann.  Neuroimmunology and neuroinflammation in autoimmune, neurodegenerative and psychiatric disease , 2018, Immunology.

[23]  M. Staufenbiel,et al.  Innate immune memory in the brain shapes neurological disease hallmarks , 2018, Nature.

[24]  L. Ignatowicz,et al.  The mechanisms shaping the repertoire of CD4+ Foxp3+ regulatory T cells , 2018, Immunology.

[25]  D. Standaert,et al.  Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease , 2018, Experimental Neurology.

[26]  C. Dobson,et al.  Immunization with α‐synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model , 2018, Glia.

[27]  C. Dobson,et al.  Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers , 2017, Science.

[28]  H. Weiner,et al.  CNS inflammation and neurodegeneration. , 2017, The Journal of clinical investigation.

[29]  R. Thangavel,et al.  Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration , 2017, Front. Cell. Neurosci..

[30]  Pengfei Wang,et al.  The correlation of lymphocyte subsets, natural killer cell, and Parkinson’s disease: a meta-analysis , 2017, Neurological Sciences.

[31]  C. Ritchie,et al.  CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2017, The Cochrane database of systematic reviews.

[32]  D. Gómez-Almaguer,et al.  Altered CSF cytokine network in amyotrophic lateral sclerosis patients: A pathway‐based statistical analysis , 2017, Cytokine.

[33]  J. Winkler,et al.  α-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses , 2016, Journal of Neuroinflammation.

[34]  R. Ransohoff.  How neuroinflammation contributes to neurodegeneration , 2016, Science.

[35]  F. Quintana,et al.  Tolerogenic nanoparticles inhibit T cell–mediated autoimmunity through SOCS2 , 2016, Science Signaling.

[36]  C. Dobson,et al.  Chaperome screening leads to identification of Grp94/Gp96 and FKBP4/52 as modulators of the α‐synuclein‐elicited immune response , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  Salvador Ventura,et al.  Protein misfolding diseases , 2015, Future science OA.

[38]  T. Ben-Hur,et al.  Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson’s Disease , 2015, Scientific Reports.

[39]  A. Emelyanov,et al.  Plasma Oligomeric Alpha‐Synuclein Is Associated With Glucocerebrosidase Activity in Gaucher Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[40]  J. Trojanowski,et al.  Spreading of pathology in neurodegenerative diseases: a focus on human studies , 2015, Nature Reviews Neuroscience.

[41]  C. Dobson,et al.  Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity. , 2014, ACS chemical biology.

[42]  C. Dobson,et al.  The amyloid state and its association with protein misfolding diseases , 2014, Nature Reviews Molecular Cell Biology.

[43]  M. Lynch.  The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease , 2014, Immunology.

[44]  C. Dobson,et al.  Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation , 2013, PloS one.

[45]  F. Pedata,et al.  Amyloid-β oligomer synaptotoxicity is mimicked by oligomers of the model protein HypF-N , 2013, Neurobiology of Aging.

[46]  I. Campbell,et al.  Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype , 2013, Glia.

[47]  M. Lynch,et al.  IFN-γ Production by Amyloid β–Specific Th1 Cells Promotes Microglial Activation and Increases Plaque Burden in a Mouse Model of Alzheimer’s Disease , 2013, The Journal of Immunology.

[48]  Leonore A. Herzenberg,et al.  Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis , 2012, Science Translational Medicine.

[49]  C. Dobson,et al.  Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers , 2012, Proceedings of the National Academy of Sciences.

[50]  F. Chiti,et al.  Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships. , 2012, Chemistry & biology.

[51]  J. Landowski,et al.  Beta-Amyloid Peptides Enhance the Proliferative Response of Activated CD4+CD28+ Lymphocytes from Alzheimer Disease Patients and from Healthy Elderly , 2012, PloS one.

[52]  Dan Peer,et al.  Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.

[53]  N. Kuriyama,et al.  Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease , 2012, Geriatrics & gerontology international.

[54]  S. Cheon,et al.  Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease , 2011, Journal of clinical neurology.

[55]  F. Chiti,et al.  A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells , 2011, Journal of cellular and molecular medicine.

[56]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[57]  Michele Vendruscolo,et al.  Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions , 2011, Cell.

[58]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[59]  D. Dickson,et al.  IFN-γ Promotes Complement Expression and Attenuates Amyloid Plaque Deposition in Amyloid β Precursor Protein Transgenic Mice , 2010, The Journal of Immunology.

[60]  Fabrizio Chiti,et al.  A causative link between the structure of aberrant protein oligomers and their toxicity. , 2010, Nature chemical biology.

[61]  Maria L. D. Udan,et al.  Oligomeric amyloid-β(1–42) induces THP-1 human monocyte adhesion and maturation , 2009, Brain Research.

[62]  Weiming Xia,et al.  A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. , 2009, Archives of neurology.

[63]  T. Suuronen,et al.  Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology , 2008, Journal of cellular and molecular medicine.

[64]  C. Dobson,et al.  Immunological features of α-synuclein in Parkinson's disease , 2008, Journal of cellular and molecular medicine.

[65]  K. Moore,et al.  The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.

[66]  F. Chiti,et al.  Conformational properties of the aggregation precursor state of HypF-N. , 2008, Journal of Molecular Biology.

[67]  Christopher M. Dobson,et al.  Prefibrillar Amyloid Aggregates Could Be Generic Toxins in Higher Organisms , 2006, The Journal of Neuroscience.

[68]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  C. Dobson,et al.  Amyloid formation from HypF-N under conditions in which the protein is initially in its native state. , 2005, Journal of molecular biology.

[71]  M. Bolognesi,et al.  Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. , 2004, Journal of molecular biology.

[72]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[73]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[74]  C. Dobson,et al.  Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N‐terminal domain , 2001, Protein science : a publication of the Protein Society.

[75]  C M Dobson,et al.  Designing conditions for in vitro formation of amyloid protofilaments and fibrils. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  C. Brodie,et al.  T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. , 1995, Clinical immunology and immunopathology.

[77]  C. Roodveldt,et al.  The 'Omics' of Amyotrophic Lateral Sclerosis. , 2016, Trends in molecular medicine.

[78]  D. Standaert,et al.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. , 2015, Journal of Parkinson's disease.

[79]  E. Calabrese,et al.  PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[80]  A. Goate,et al.  Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.